Abivax SA is a clinical-stage biotechnology company committed to developing cutting-edge immunotherapies for chronic inflammatory diseases and viral infections. Its lead candidate, ABX464, is currently undergoing clinical trials for indications such as ulcerative colitis, leveraging a distinctive strategy that combines antibody-mediated therapies with innovative proprietary compounds. With a strong pipeline and a dedicated team of experienced scientists, Abivax aims to address significant unmet medical needs, positioning itself as a compelling investment choice for institutional investors looking to capitalize on emerging opportunities in the immunotherapy sector.
| Revenue (TTM) | $4.92M |
| Gross Profit (TTM) | $4.92M |
| EBITDA | $-254.00M |
| Operating Margin | -4184.00% |
| Return on Equity | -157.10% |
| Return on Assets | -44.70% |
| Revenue/Share (TTM) | $0.07 |
| Book Value | $6.20 |
| Price-to-Book | 23.60 |
| Price-to-Sales (TTM) | 2454.32 |
| EV/Revenue | 157.63 |
| EV/EBITDA | -12.66 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 35.20% |
| Shares Outstanding | $87.16M |
| Float | $48.12M |
| % Insiders | 0.00% |
| % Institutions | 70.62% |
Shares of Abivax NASDAQ: ABVX were up more than 40% in the month ending July 6, after the company announced positive results from its late-stage (Phase 3) trial of its lead candidate, Obefazimod, which is being designed as a long-term maintenance treatment for ulcerative colitis (UC). The rally pushed ABVX nearly to its all-time high of $146.41, set in December 2025.
Abivax Announces Closing of $920 Million Public Offering PARIS, France, July 6, 2026 –10:05 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announces the closing of its previously announced underwritten public offering of 7,360,000 American Depositary Shares (“ADSs”), each representing one ordinary share, €0.01 nominal value per share (each an “Ordinary Share”), of the Company, in the United States (the “Offering”), which includes the full exercise of the underwriters' option to purchase additional ADSs (the “Underwriters' Option”).
Shares rose 5% after the biotech moved to bolster its balance sheet through an upsized stock offering, signaling investor appetite in the wake of positive clinical-trial data.
Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $920M (€807M)
Abivax SA raised $800 million in an expanded share sale on Wednesday after strong investor demand, valuing the French biotechnology company at nearly $11 billion and easing pressure to pursue a near-term sale.
Abivax Announces Pricing of Highly Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax announces trading resumption of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 02:50 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced the trading resumption of its ordinary shares on the regulated market of Euronext Paris as from 3:30 p.m.
Abivax Announces Pricing of Oversubscribed and Upsized $800M (€702M) Public Offering of American Depositary Shares
Abivax announces temporary trading halt of its ordinary shares on Euronext Paris PARIS, France, July 1, 2026 – 07:30 a.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, announced today that trading of its ordinary shares on the regulated market of Euronext Paris (“Euronext Paris”) will be temporarily halted, at the Company's request, from the opening of the market at 9:00 a.m.
Abivax Announces Launch of Public Offering of American Depositary Shares PARIS, France – June 30, 2026 – 10:45 p.m. CEST – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the launch of an underwritten public offering of approximately $600 million (approximately €527 million) of its American Depositary Shares (“ADSs”), each representing one ordinary share of Abivax, nominal value €0.01 per share (each, an “Ordinary Share”), in the United States (the “Offering”).
